Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ekdoin, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop planting, inspection, technical advisory, and asset investment activities. The company was incorporated in 2010 and is based in Yining, China. Yili Chuanning Biotechnology Co.,Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Metrics to compare | 301301 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship301301PeersSector | |
---|---|---|---|---|
P/E Ratio | 20.9x | 37.6x | −0.5x | |
PEG Ratio | 1.02 | −1.39 | 0.00 | |
Price/Book | 3.4x | 2.3x | 2.6x | |
Price / LTM Sales | 5.0x | 7.2x | 3.3x | |
Upside (Analyst Target) | 20.4% | 4.1% | 43.5% | |
Fair Value Upside | Unlock | 10.9% | 6.9% | Unlock |